LPL Financial’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$48.6M Buy
1,322,929
+100,264
+8% +$4.75M 0.01% 934
2025
Q4
$62.2M Sell
1,222,665
-176,868
-13% -$9.04M 0.02% 771
2025
Q3
$77.7M Sell
1,399,533
-86,886
-6% -$5.09M 0.02% 637
2025
Q2
$103M Buy
1,486,419
+107,212
+8% +$7.29M 0.03% 472
2025
Q1
$95.6M Buy
1,379,207
+23,140
+2% +$1.91M 0.04% 439
2024
Q4
$117M Sell
1,356,067
-6,715
-0.5% -$726K 0.05% 351
2024
Q3
$162M Buy
1,362,782
+47,496
+4% +$6.33M 0.07% 238
2024
Q2
$188M Buy
1,315,286
+140,671
+12% +$18.6M 0.09% 191
2024
Q1
$151M Buy
1,174,615
+237,444
+25% +$28.3M 0.08% 220
2023
Q4
$97M Buy
937,171
+176,325
+23% +$17.4M 0.06% 293
2023
Q3
$69.2M Buy
760,846
+158,628
+26% +$14M 0.05% 346
2023
Q2
$48.7M Buy
602,218
+89,402
+17% +$7.3M 0.03% 459
2023
Q1
$40.8M Buy
512,816
+30,052
+6% +$2.13M 0.03% 474
2022
Q4
$32.7M Buy
482,764
+11,844
+3% +$694K 0.03% 512
2022
Q3
$23.5M Buy
470,920
+33,124
+8% +$1.77M 0.02% 580
2022
Q2
$24.4M Sell
437,796
-1,492
-0.3% -$82.8K 0.02% 570
2022
Q1
$24.4M Buy
439,288
+5,316
+1% +$273K 0.02% 589
2021
Q4
$24.3M Sell
433,972
-1,036
-0.2% -$56.1K 0.02% 603
2021
Q3
$20.9M Buy
435,008
+52,214
+14% +$2.52M 0.02% 613
2021
Q2
$16M Buy
382,794
+35,228
+10% +$1.37M 0.02% 677
2021
Q1
$11.7M Buy
347,566
+12,316
+4% +$439K 0.01% 752
2020
Q4
$11.7M Buy
335,250
+65,560
+24% +$2.27M 0.02% 682
2020
Q3
$9.36M Buy
269,690
+27,328
+11% +$911K 0.01% 676
2020
Q2
$7.93M Sell
242,362
-20,158
-8% -$643K 0.01% 675
2020
Q1
$7.9M Sell
262,520
-25,330
-9% -$754K 0.02% 586
2019
Q4
$8.33M Sell
287,850
-34,902
-11% -$966K 0.02% 645
2019
Q3
$8.34M Buy
322,752
+41,618
+15% +$1.05M 0.02% 600
2019
Q2
$7.17M Buy
281,134
+32,906
+13% +$813K 0.02% 637
2019
Q1
$6.49M Buy
248,228
+18,470
+8% +$454K 0.01% 657
2018
Q4
$5.29M Buy
229,758
+50,990
+29% +$1.13M 0.01% 665
2018
Q3
$4.21M Buy
178,768
+2,318
+1% +$56.6K 0.01% 820
2018
Q2
$4.07M Sell
176,450
-5,978
-3% -$142K 0.01% 798
2018
Q1
$4.49M Buy
182,428
+71,174
+64% +$1.87M 0.01% 739
2017
Q4
$2.99M Sell
111,254
-20,280
-15% -$516K 0.01% 862
2017
Q3
$3.17M Buy
131,534
+64,570
+96% +$1.46M 0.01% 779
2017
Q2
$1.44M Buy
66,964
+52,724
+370% +$1.06M 0.01% 1139
2017
Q1
$245K Sell
14,240
-15,312
-52% -$267K ﹤0.01% 2354
2016
Q4
$531K Buy
29,552
+820
+3% +$14.9K ﹤0.01% 1705
2016
Q3
$584K Buy
28,732
+3,652
+15% +$90.5K 0.01% 1574
2016
Q2
$675K Sell
25,080
-145,028
-85% -$3.98M 0.01% 1436
2016
Q1
$4.69M Sell
170,108
-6,678
-4% -$179K 0.01% 748
2015
Q4
$5.13M Buy
176,786
+80,700
+84% +$2.23M 0.01% 709
2015
Q3
$2.65M Buy
96,086
+8,130
+9% +$230K 0.01% 710
2015
Q2
$2.41M Buy
87,956
+15,334
+21% +$431K 0.01% 818
2015
Q1
$1.98M Sell
72,622
-3,508
-5% -$80.8K 0.01% 915
2014
Q4
$1.61M Sell
76,130
-12,356
-14% -$276K 0.01% 1016
2014
Q3
$2.12M Sell
88,486
-23,554
-21% -$542K 0.01% 832
2014
Q2
$2.59M Sell
112,040
-18,732
-14% -$414K 0.02% 744
2014
Q1
$2.98M Sell
130,772
-69,278
-35% -$1.48M 0.02% 646
2013
Q4
$3.7M Buy
200,050
+25,950
+15% +$452K 0.02% 542
2013
Q3
$2.95M Buy
174,100
+10,740
+7% +$181K 0.02% 607
2013
Q2
$2.53M Buy
+163,360
New +$2.72M 0.02% 616

Other funds holding NVO

LPL Financial's NVO Position: Q1 2026 in Review

LPL Financial increased its Novo Nordisk (NVO) stake by 8.2% in Q1 2026, buying an estimated $4.75M and bringing the position to 1,322,929 shares worth $48.6M. The position accounts for 0.01% of the portfolio, ranked #934.

LPL Financial first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $188M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • LPL Financial held 1,322,929 shares of Novo Nordisk worth $48.6M as of Q1 2026.
  • LPL Financial bought 100,264 Novo Nordisk shares in Q1 2026, an estimated $4.75M.
  • Novo Nordisk made up 0.01% of LPL Financial's portfolio in Q1 2026, its #934 holding.
  • LPL Financial first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • LPL Financial's Novo Nordisk position peaked at $188M in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.